Overview

Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 clinical trial is to evaluate the safety, tolerability and efficacy of AC102 administered as single intratympanic injection compared to oral steroid treatment in patients with Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL).
Phase:
Phase 2
Details
Lead Sponsor:
AudioCure Pharma GmbH
Treatments:
Prednisolone